The execution management system (EMS) is increasingly becoming an important part of the trading workflow. Firms are turning to advanced components of the EMS that can be plugged into their existing technology without disruption.
- Established firms seeking to enhance their execution capabilities are increasingly turning to advanced execution management system (EMS) components that can be seamlessly plugged into their existing technology stacks, with little disruption to workflow.
- Hedge funds are increasingly augmenting their existing technology stack with state-of-the-art EMSs, such as the TORA, an LSEG business, EMS, which provides a comprehensive set of features and capabilities that helps firms in their pursuit of efficient and optimised trade execution.
- Changing an order management system (OMS) is analogous to changing the engine of a car, changing an EMS should be like changing the tyres, i.e. far less disruptive.
In today’s highly competitive financial markets, hedge funds are constantly seeking innovative ways to gain an edge over their competitors. One key area of focus is the trading process itself, where advanced execution management system (EMS) components are being used by established firms looking to enhance their execution capabilities.
Forward-looking firms now realise that following this ‘best-of-breed’ approach can provide them with the EMS capabilities they need to navigate complex trades and multi-asset strategies with ease, while streamlining their operations and enhancing their overall trading performance in the process.
The weakest link?
When first launching, hedge funds are often drawn to ‘all-in-one’ solutions that provide front-to-back portfolio management, order management and execution management capabilities via a single solution.
As we’ve discussed before, this makes perfect sense, as new funds often have limited resources for the various tasks they have to perform.
Adopting multiple solutions from different vendors can be costly and onerous, often requiring multiple implementations and integrations. Workflow between systems can be cumbersome, and potential compatibility issues can lead to an excess of fail points. An all-in-one approach can ostensibly give them everything they need in a single solution from day one.
However, with many ‘all-in-one’ solutions, the EMS component is often the weakest link, particularly if the solution has come about as a result of a vendor stitching products together following mergers and acquisitions, or if a legacy portfolio management or order management system has been expanded to include some EMS capabilities, for example.
This can be a problem for hedge funds as they grow, as their needs become more complex, and as they find themselves constrained by the limitations of their systems.
What the execution management system should offer
To get around these limitations, a number of hedge funds are now augmenting their existing technology stack with state-of-the-art EMSs, such as the TORA EMS, which provides a comprehensive set of features and capabilities that empowers firms in their pursuit of efficient and optimised trade execution.
To ensure maximum flexibility and comprehensive market coverage, the EMS should provide multi-asset and multi-market support to enable trading across various asset classes, such as equities, fixed income, commodities, and foreign exchange, while providing access to multiple market venues, including exchanges, alternative trading systems, and dark pools.
Funds looking to manage complex trading strategies such as pairs, baskets, lists, and program trades need advanced functionality and tools within the EMS to execute orders for multiple securities simultaneously, monitor and manage positions, and adjust execution parameters dynamically based on market conditions or portfolio requirements.
The EMS should offer the ability to connect with multiple brokers across various geographic locations. This ensures that the fund has access to a diverse range of liquidity providers, execution services, and local market expertise, enabling the firm to capitalise on global opportunities and navigate different regulatory environments.
By seamlessly integrating with numerous brokers, the EMS can help hedge funds enhance their trading reach, optimise execution, and diversify counterparty risks.
Rules-based smart order routing capabilities are needed to allow hedge funds to optimise their trade execution based on factors such as price, liquidity, speed, and market impact.
By intelligently routing orders to the most suitable execution venue, the EMS can help hedge funds achieve better execution, reduce trading costs, and enhance overall trading performance.
Advanced functionality should be provided for handling complex allocation scenarios, including the ability to allocate trades across multiple accounts, portfolios, and investment strategies based on customisable rules and criteria, such as pre-trade allocation models, percentage breakdowns, or specific investment mandates.
By supporting complex allocation, the EMS enables funds to efficiently manage their trade executions while maintaining proper diversification, risk exposure, and compliance with investment guidelines.
Advanced algorithmic trading capabilities are needed to allow hedge funds to develop, test, and deploy custom strategies that enable efficient execution, exploit market inefficiencies, and minimise the market impact of trades, along with real-time analytics and monitoring tools to enable traders to assess market conditions, track individual trades, and manage positions, empowering them to make informed decisions and quickly react to changing market dynamics.
Integrated risk management tools, including real-time monitoring, alerts, and the ability to adjust trading parameters dynamically to maintain the desired risk profile should be included to help firms assess and manage the risks associated with their trading strategies.multi-asset and multi-market
A modern, well-designed EMS should have well-documented APIs that allow it to easily and seamlessly integrate with other systems, such as order management systems, portfolio management platforms, risk management tools, and other internal and external applications.
Regulatory compliance should be facilitated by the EMS’s ability to automatically generate necessary reports, maintain an audit trail of trading activities, and provide tools to monitor and manage compliance risks in real time.
Finally, the EMS should be built on a high-performance infrastructure that minimises latency and ensures reliable trade execution. This is crucial for hedge funds employing high-frequency or latency-sensitive trading strategies.
Changing the tyres
For established hedge funds looking to enhance their execution management capabilities, the TORA EMS provides all of the above features and functions, and more.
Plugging the TORA EMS into a firm’s existing trading technology stack does not have to be too difficult, costly or disruptive.
TORA’s EMS is architected in such a way that it can be implemented to either augment or replace a firm’s existing EMS with very little disruption to the firm’s trading workflow, which means that customers benefit from our extensive and comprehensive execution management functionality without having to change how they work or completely strip out existing systems.
If changing an OMS is analogous to changing the engine of a car, changing an EMS should be like changing the tyres, i.e. far less disruptive.
At TORA, we believe that technology solutions should be able to grow with their clients.
Start-ups can very quickly grow in assets under management, in complexity, in the number of funds they manage, in the assets they trade and in the regions in which they operate.
The TORA platform – built around a microservices architecture, allowing each service to be scaled and deployed individually to meet the needs of the client – is designed to support that growth.
Republication or redistribution of LSE Group content is prohibited without our prior written consent.
The content of this publication is for informational purposes only and has no legal effect, does not form part of any contract, does not, and does not seek to constitute advice of any nature and no reliance should be placed upon statements contained herein. Whilst reasonable efforts have been taken to ensure that the contents of this publication are accurate and reliable, LSE Group does not guarantee that this document is free from errors or omissions; therefore, you may not rely upon the content of this document under any circumstances and you should seek your own independent legal, investment, tax and other advice. Neither We nor our affiliates shall be liable for any errors, inaccuracies or delays in the publication or any other content, or for any actions taken by you in reliance thereon.
Copyright © 2023 London Stock Exchange Group. All rights reserved.
The content of this publication is provided by London Stock Exchange Group plc, its applicable group undertakings and/or its affiliates or licensors (the “LSE Group” or “We”) exclusively.
Neither We nor our affiliates guarantee the accuracy of or endorse the views or opinions given by any third party content provider, advertiser, sponsor or other user. We may link to, reference, or promote websites, applications and/or services from third parties. You agree that We are not responsible for, and do not control such non-LSE Group websites, applications or services.
The content of this publication is for informational purposes only. All information and data contained in this publication is obtained by LSE Group from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data are provided "as is" without warranty of any kind. You understand and agree that this publication does not, and does not seek to, constitute advice of any nature. You may not rely upon the content of this document under any circumstances and should seek your own independent legal, tax or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither We nor our affiliates shall be liable for any errors, inaccuracies or delays in the publication or any other content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the publication and its content is at your sole risk.
To the fullest extent permitted by applicable law, LSE Group, expressly disclaims any representation or warranties, express or implied, including, without limitation, any representations or warranties of performance, merchantability, fitness for a particular purpose, accuracy, completeness, reliability and non-infringement. LSE Group, its subsidiaries, its affiliates and their respective shareholders, directors, officers employees, agents, advertisers, content providers and licensors (collectively referred to as the “LSE Group Parties”) disclaim all responsibility for any loss, liability or damage of any kind resulting from or related to access, use or the unavailability of the publication (or any part of it); and none of the LSE Group Parties will be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, howsoever arising, even if any member of the LSE Group Parties are advised in advance of the possibility of such damages or could have foreseen any such damages arising or resulting from the use of, or inability to use, the information contained in the publication. For the avoidance of doubt, the LSE Group Parties shall have no liability for any losses, claims, demands, actions, proceedings, damages, costs or expenses arising out of, or in any way connected with, the information contained in this document.
LSE Group is the owner of various intellectual property rights ("IPR”), including but not limited to, numerous trademarks that are used to identify, advertise, and promote LSE Group products, services and activities. Nothing contained herein should be construed as granting any licence or right to use any of the trademarks or any other LSE Group IPR for any purpose whatsoever without the written permission or applicable licence terms.